

| Short Name | Comments | Type | Investigator | Contact |
|------------------------------|--|---------------------|---|--|
| Disease site specific | | | | |
| MSTA | Musculoskeletal Tumor Tissue Acquisition Protocol | Molecular Profiling | Steensma, Matthew | Heidi De Vries cancer.research@spectrumhealth.org (616) 486-8500 |
| | <i>This study will collect biospecimens and medical information for use in laboratory research to learn more about bone tumors and musculoskeletal diseases. Future research is focused on the prevention, diagnosis and treatment.</i> | | | |
| Genetic Outlier | The Identification of Novel Mutations in Outlier Patients | Biobanking | Steensma, Matthew | Heidi De Vries cancer.research@spectrumhealth.org (616) 486-8500 |
| | <i>This study is to better understand more about germline mutations (hereditary mutations) in those that have unique circumstances surrounding their medical condition or the medical condition of a family member. Researchers are looking to develop a mechanism for discovery-level genetic research in individuals who have characteristics of a genetic disease or syndrome which cannot currently be linked to a known germline mutation. Participation is by invitation only.</i> | | | |
| AOST1321 | COG-AOST1321: Phase 2 Study of <u>Denosumab</u>, a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma - Partial Closure to Accrual: Stratum 1 (Stage 1 of Cohort 1.) Patients Must be Equal to or Greater than 11 Years of Age but Less than 50 Years of Age at the Time of Enrollment For More Information | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| AOST1421 | COG-AOST1421: A Phase II Study of Human-Mouse <u>Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18</u> in Combination with Sargramostim in Patients with Recurrent Osteosarcoma. Patients Must be Less than 30 Years of Age at Enrollment For More Information | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |

| | | | | |
|---|---|-----------|---|--|
| AEWS1221 | COG-AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody <i>Ganitumab</i> to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma. Patients \leq 50 of Age at Enrollment will be Eligible for this Study For More Information | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| ARST1321 | COG-ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS.) A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus <i>Pazopanib</i> . Partial Closure: Part 1 (dose-finding phase) for the Non-chemotherapy Cohort. Patients Must be \geq 2 years at the Time of the Biopsy that Established the Diagnosis of NRSTS will be Eligible For More Information | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| Femoral Met Repair | A Prospective, Randomized Surgical Trial Comparing Postoperative Functional Outcomes Among Cancer Patients Treated with Long-stem Cemented Hemiarthroplasty (LSCH) versus Intramedullary Nail (IMN) for Pathologic Subtrochanteric Femur Fractures | Treatment | Steensma, Matthew | Heidi De Vries cancer.research@spectrumhealth.org (616) 486-8500 |
| <i>This study is being done to look at two different types of surgeries routinely used for treating metastases, the spread of cancer in the upper portion of the femur.</i> | | | | |
| Protocols that are NOT disease site specific | | | | |
| Treatment | | | | |
| Alexion ALXN6000-ONC-102 | Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| | A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |

Sarcoma

| | | | | |
|-----------------------|---|-----------|---|---------------------------------|
| | A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| | A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| | A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| BGB-290 | A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| ALEXO AT148001 | Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| | A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| SCI-CD47-001 | First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| MK-4280-001 | A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| LZM009-001 | A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |

| | | | | |
|-----------------------------|---|-----------|---|---------------------------------|
| ASN002 | A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| 20150195 AMG 820 | A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| R3767-ONC-1613 | A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| CP-MGA012-01 | A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| MK-4820 | A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| ASN003-101 | A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| MK-8353-013 | A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| 5F9004 | A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |

| | | | | |
|---------------------|---|-----------|---|---|
| CP-MGA012-01 | A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| CVM-001 | A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| APX_CLN_0011 | A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| CPI-1205-202 | A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors | Treatment | START Midwest Investigators | START Midwest (616) 954-5554 |
| NRG CC003 | Randomized Phase II/III Trial of Prophylactice Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| NRG CC001 | A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| A071401 | Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations | Treatment | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |

| <i>Molecular Profiling</i> | | | | |
|----------------------------|---|------------------------|---|---|
| QOL Multisite EAQ-152 | EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - MATCH | MOLECULAR ANALYSIS / ADVANCED REFRACTORY SOLID TUMORS OR LYMPHOMAS; Targeted Therapy Directed by Genetic Testing – See sub-protocols below | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 | <i>Dasatinib</i> in Patients with Tumors with DDR2 Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - A | Solid Tumors (Other than SC & NSCLC) or Lymphomas; <i>Afatinib</i> in Patients that have Activating Mutations of EGFR and Have Progressed After Standard Treatment | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - B | Tumors with HER2 Activating Mutations; Treatment: <i>Afatinib</i> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - C1 | <i>Crizotinib</i> in Patients with Tumors with MET Amplification | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - C2 | <i>Crizotinib</i> in Patients with Tumors with MET Exon 14 Deletion | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |

| | | | | |
|------------|--|---------------------|---|--|
| EAY131 - E | Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u>AZD9291</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - F | Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u>Crizotinib</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - G | ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u>Crizotinib</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - H | Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u>Dabrafenib</u> and <u>Trametinib</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - J | <u>Trametinib</u> and <u>Pertuzumab</u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - L | Phase II Study of MLN0128 (<u>TAK-228</u>) in Patients with Tumors with mTOR Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - M | Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - R | BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |

| | | | | |
|-------------|--|---------------------|---|---|
| EAY131 - S1 | <u>Trametinib</u> in Patients with Tumors with NF1 Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - S2 | <u>Trametinib</u> in Patients with Tumors with GNAQ or GNA 11 Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - T | Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u>GDC-0449 (vismodegib)</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - V | Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u>Sunitinib</u> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - W | Phase II Study of <u>AZD4547</u> in Patients with Tumors with Aberrations in the FGFR Pathway | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - X | <u>Dasatinib</u> in Patients with Tumors with DDR2 Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - Y | <u>AZD5363</u> in Patients with Tumors with AKT Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |

| | | | | |
|----------------------|--|---------------------|---|---|
| EAY131 - Z1A | <i>Binimetinib</i> in Patients with Tumors (Other than Melanoma) with NRAS Mutations | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - Z1B | MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - Z1D | <i>Nivolumab</i> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer) | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - Z1E | Testing <i>LOXO-101</i> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes | | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| EAY131 - Z1I | Testing <i>AZD1775</i> as a Possible Treatment in People who have Cancer with BRCA Mutations | | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| ASCO TAPUR | Targeted Agent and Profiling Utilization Registry Study. <i>All Drugs Provided</i> | Molecular Profiling | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |
| Biorepository | | | | |
| NCI PDM 9846 | Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI) | Biobanking | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| | For More Information | | | |

| | | | | |
|------------------------------|---|--------------------|---|---|
| SHARE | The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators <i>This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.</i> | Biobanking | Cottingham, Sandra | Spectrum Health Biorepository david.chesla@spectrumhealth.org (616) 267-2629 |
| Assessment/ Education | | | | |
| URCC 13059 GAP-70 | Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults For More Information | Other | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| Symptom Management | | | | |
| S1415CD | A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) For More Information | Symptom Management | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| URCC 04040 YOCAS | A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors For More Information | Symptom Management | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |
| URCC 16070 | Treatment of Refractory Nausea For More Information | Symptom Management | CRCWM Physician Investigators | CRCWM (616) 391-1230 www.crcwm.org |